Bone Therapeutics

[Ivel]

De 3 al bijna zichtbaar in het boekje

2,8 3.465 5

2,84 300 1

2,85 2.010 4

2,86 50 1

2,87 1.500 1

2,88 2.436 2

2,89 2.323 4

2,9 4.730 2

2,93 1.000 1

2,95 5.730 3

Het is al bijna zover
Wat een rally

[TomW]

Enig idee wat er aan de hand is ?
Of is het heel laattijdige reactie op China deal ???

[bertje]

Laatste (13/10/20 - 14:04)
3,08
Wijziging (0,48)
18,46%

[bertje]

Enig idee wat er aan de hand is ?
Of is het heel laattijdige reactie op China deal ???

Morgen mogen ze voor europa praten.
https://www.meetingonthemesa.com/agenda/

[dandev]

Bone Therapeutics’ allogeneic cell therapy product, ALLOB, shows 90% fusion rate at 24 months in Phase IIa study in lumbar spinal fusion





90% of patients show bone fusion as well as strong clinical improvements in function and pain at 24 months follow-up period with a good product safety profile







Gosselies, Belgium, 14 October 2020, 7am CEST – BONE THERAPEUTICS (Euronext Brussels and Paris: BOTHE), the cell therapy company addressing unmet medical needs in orthopedics and other diseases, today announces positive 24-month follow-up results for the Phase IIa study with the allogeneic cell therapy product, ALLOB, in patients undergoing lumbar spinal fusion procedures.

The 24-month data show a high percentage of successful lumbar vertebrae fusion of 90%. Patients also continue to experience important clinical improvements in function and pain, from as early as six months after treatment, up to the 24-month follow-up period.

“Degenerative spine disorders have a major impact on the quality of life of patients. These impacts include decreases in the stability of the spine and pain in motion,” said Dr. Alphonse Lubansu, M.D., Head of the Spinal Clinic, Erasme University Hospital, Université libre de Bruxelles. “The 24 month follow-up data of this Phase IIa clinical trial have demonstrated that patients treated with ALLOB in spinal fusion procedure show a high incidence in fusion, and benefit from a sustained, clinically meaningful improvement in function and pain throughout the 24 months following treatment together with a good safety profile. These results show that ALLOB in combination with the standard spine fusion surgery could be a promising treatment option to address the currently unmet needs of these patients.”

“This positive data for lumbar spinal fusion complements the strong Phase I/IIa results from ALLOB in patients with delayed union fractures,” said Miguel Forte, MD, PhD, Chief Executive Officer of Bone Therapeutics. “These studies provide promising clinical evidence for the potential of Bone Therapeutics’ unique allogeneic cell therapy platform to address high unmet medical needs in orthopaedics and bone related disorders. We will now hold discussions with global regulators and our partners to explore a variety of options for the next stages of clinical development for ALLOB in different orthopedic indications, while pursuing the phase IIb study of ALLOB in difficult tibial fractures. In addition, the clinical results provide further evidence for the expansion of ALLOB and our platform of differentiated MSCs to other indications.”

The multi-center, open-label proof-of-concept Phase IIa study was designed to evaluate the safety and efficacy of ALLOB administered, procedure in which an interbody cage with bioceramic granules mixed with ALLOB is implanted into the spine to achieve fusion of the lumbar vertebrae. The main endpoints of the 24-month follow-up analysis included safety and radiological assessments to evaluate vertebrae fusion (continuous bone bridges) and clinical assessments to evaluate improvement in patients’ functional disability as well as reduction in back and leg pain. The study evaluated 30 patients treated with ALLOB, 29 patients attended the 24-month visit.

Radiological data was collected from CT-scans at 24 months and assessed by three external readers. It showed a successful fusion of the lumbar vertebrae in 27 out of 30 patients (90%). In addition, the remaining 3 patients showed radiological evidence of bone formation. Treatment with ALLOB also resulted in a clear and statistically significant clinical improvement in function and reduction in pain over the 24-month follow-up period. Functional disability improved from the pre-treatment baseline to 24-month by a mean score of 60% (p<0.001) on the Oswestry Disability Index(1). Back and leg pain were strongly reduced by 57 to 62% (p<0.001) and 68 to 70% (p<0.001) respectively compared to pre-treatment baseline. Treatment with ALLOB was generally well-tolerated by the patients, consistent with previous reported results.

[TomW]

Mooie resultaten (alweer). De technologie werkt echt wel ! Nu hopen dat ze de juiste keuzes maken (partners, markten, …)

[El Dinero]

We zouden nu toch met gemak naar 4 euro moeten kunnen gaan met dergelijke outlook.
Ik doe ze nog niet weg in elk geval

[El Dinero]

Gisteren winstnemingen, voor de rest nog weinig verkooporders tot 3.5
Heb er nog wat aangekocht voor de LT

[Ivel]

Ziet er goed uit voor LT
Ik was wel verwonderd dat de koers nog zo omhoog ging na de resultaten van Allob lumbale wervelfusie, de resultaten van het 24 maanden onderzoek (90% succesvolle fusie) stonden namelijk al enkele weken in de vernieuwde bedrijfspresentatie op de website.

[jack.]

Bone goed op weg met JTA-004 Fase III studie
Gepubliceerd op 20 oktober 2020 07:22 |
07:22 - Bone goed op weg met JTA-004 Fase III studie
Bone Therapeutics (19 okt)
EUR 3,110 0,000 (0,00%)

(ABM FN) Bone Therapeutics heeft al 50 procent van de patiënten voor knieartrose behandeld in de Fase III studie met JTA-004 waarvoor de rekrutering goed onderweg is. Dit liet het biotechbedrijf dinsdagochtend weten.

In het huidige tempo waarin Bone patiënten werft en in de veronderstelling dat de ontwikkeling van de COVID-19-pandemie niet zal leiden tot een verdere significante verstoring binnen de wereldwijde gezondheidszorg, verwacht Bone de rekrutering van patiënten voor het einde van 2020 te kunnen afronden.


De resultaten voor het primaire eindpunt na 3 maanden en de evaluatieperiode na 6 maanden worden in de tweede helft van 2021 verwacht, aldus Bone.

Misschien iets voor GLPG om samen te werken of overname ?